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Abstract 
Since late 2019, the novel coronavirus SARS-CoV-2 has introduced a wide array of health 
challenges globally. In addition to a complex acute presentation that can affect multiple organ 
systems, increasing evidence points to long-term sequelae being common and impactful. The 
worldwide scientific community is forging ahead to characterize a wide range of outcomes 
associated with SARS-CoV-2 infection; however the underlying assumptions in these studies 
have varied so widely that the resulting data are difficult to compareFormal definitions are 
needed in order to design robust and consistent studies of Long COVID that consistently 
capture variation in long-term outcomes. Even the condition itself goes by three terms, most 
widely “Long COVID”, but also “COVID-19 syndrome (PACS)” or, “post-acute sequelae of 
SARS-CoV-2 infection (PASC)”. In the present study, we investigate the definitions used in the 
literature published to date and compare them against data available from electronic health 
records and patient-reported information collected via surveys. Long COVID holds the potential 
to produce a second public health crisis on the heels of the pandemic itself. Proactive efforts to 
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.20.21253896doi: medRxiv preprint 
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
identify the characteristics of this heterogeneous condition are imperative for a rigorous 
scientific effort to investigate and mitigate this threat. 
Introduction 
SARS-CoV-2 emerged in late 2019 as the third human coronavirus identified in the 21st 
century. As of early 2021, new impacts of the virus are still being identified. The virus initially 
targets epithelial cells, endothelial cells, alveolar macrophages (via ACE2 proteins and the 
TMPRSS2 protease) causing symptoms attributable to the lungs, digestive tract, kidneys, heart, 
brain, and other organs.1,2 Additional research has begun to explore viral presence in other 
tissues that exhibit ACE2 and TMPRSS2 expression; these include skeletal muscle, smooth 
muscle, bone, cartilage and synovia.3–6 Collectively, these symptoms constitute coronavirus 
disease 2019 (COVID-19). Individual symptoms and disease severity vary widely among 
patients, with some patients developing mild or even asymptomatic infections, while others 
experience acute respiratory distress syndrome (ARDS), sepsis, and other life-threatening 
conditions.7,8 
 
As more information about patient recovery has been collected, and as pathophysiologic 
mechanisms are revealed, a wide range of outcomes following acute COVID-19 have emerged. 
Some patients experience residual symptoms and others develop new symptoms long after the 
initial infection. These symptoms can present across a wide range of organ systems and 
tissues. Given the timeline of SARS-CoV-2’s emergence, studies to date have tracked patients’ 
clinical course up to six months post-infection,9–14 but anecdotal reports are available describing 
patients with ongoing symptoms as long as a year post-infection.15,16 Symptoms experienced after 
the acute illness represent a significant challenge for patients, physicians, and society as a 
whole. The causes, patient profile, and even symptom patterns associated with Long COVID 
remain difficult to isolate, and the natural history of this condition remains uncharacterized.  
Post-Acute Sequelae after Other Infections 
The fact that some COVID-19 patients experience symptoms following recovery from 
acute infection is not unexpected. Other infectious diseases, including Epstein-Barr Virus,17 
Giardia lamblia, Coxiella burnetii, Borrelia burgdorferi (Lyme disease) and Ross River virus,18 are 
also associated with an increased risk for post-infectious sequelae. These sequelae include 
symptoms such as disabling fatigue, musculoskeletal pain, neurocognitive difficulties, and mood 
disturbance.17–19 Chronic fatigue syndrome (CFS) is frequently preceded by a viral infection.20 
However, although these sequelae are well documented, they are still not well understood, and 
the molecular mechanisms underlying these post-acute presentations have yet to be 
elucidated.  
 
Post-infectious sequelae have also been documented following infection by other 
coronaviruses. A subset of patients with severe acute respiratory syndrome (SARS), caused by 
the coronavirus SARS-CoV, and Middle-Eastern Respiratory Syndrome (MERS), caused by the 
coronavirus MERS-CoV, were observed to experience persistent or new-onset symptoms, 
including fatigue,21 following recovery from the acute infection.21–23 For SARS, follow-ups have 
been conducted up to 15 years post-infection. In addition to fatigue, studies reported effects on 
lung health and capacity,24–27 psychological health,21 bone health,27 and lipid metabolism,28 with the 
latter two attributed to treatments involving large doses of steroids.27,28 Most of the improvements 
among SARS patients occurred within the first one to two years following infection,27,29,30 although 
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some patients continued to experience decreased quality of life for more than a decade 
following the acute illness.28 Though follow-up studies in MERS patients are more sparse, effects 
on pulmonary function were observed at one year post-infection, with patients who experienced 
more severe cases at greater risk for long-term effects.31 
Post-Acute Sequelae Following COVID-19 
While post-acute sequelae are not an unexpected outcome of SARS-CoV-2 infection, 
the number of people affected and range of symptoms associated with Long COVID is 
unprecedented. The multisystem nature of Long COVID compared to previously studied post-
acute sequelae of human coronaviruses has raised questions about how to most effectively 
identify indicators of Long COVID. An analysis of 32 symptoms in patients with and without 
SARS-CoV-2 infection identified several symptoms that were enriched in patients with COVID-
19 in comparison to other illnesses of comparable severity.32 After 30 days, loss of smell, loss of 
taste, memory loss, chest pain, and muscle weakness were the symptoms enriched in patients 
who were positive for SARS-CoV-2 at the time of their acute illness. The association between 
these symptoms and COVID-19 diagnosis fluctuated slightly at 60 and 90 days, with muscle 
weakness no longer associated at 60 days, difficulty concentrating emerging at 60 days, and 
confusion and bone or joint pain emerging at 90 days. Many of the symptoms most strongly 
associated with Long COVID are therefore distinct from those observed in post-acute SARS or 
MERS, and therefore may be challenging to identify based on research on other post-infectious 
sequelae. 
 
Furthermore, regardless of whether they are unique to Long COVID, symptoms 
frequently reported by Long COVID patients are not assessed consistently across studies. A 
systematic review available as a preprint33 evaluated all research on Long COVID released prior 
to January 1, 2021, that included at least 100 patients; based on the 15 studies that met the 
inclusion criteria, the authors identified 55 symptoms of Long COVID. None of the most 
common symptoms were assessed by all 15 studies. They reported that the five most common 
symptoms evaluated in the literature were fatigue, headache, attention disorder, hair loss, and 
dyspnea. They also reported the frequency at which clinical measurements such as chest X-ray 
and biomarkers such as C-reactive protein and D-dimer were evaluated. The authors concluded 
that the symptoms of Long COVID are extremely heterogeneous, and that the assessment of 
these symptoms varies widely among studies.  
 
However, Long COVID’s emergence has followed a different trajectory than that of most 
medical syndromes. Rather than building from a clinically determined framework of the illness, 
to date, much of the growing awareness of Long COVID and its symptoms has been driven by 
patient-led efforts.34,35 Observing residual or new symptoms months after experiencing COVID-
19, patients have established online communities to provide support and identify similarities in 
their experiences.36 Some Long COVID patients who are also researchers have led efforts to 
systematically categorize the range of experiences associated with Long COVID. An extensive 
patient-led survey (Patient-Led Research Collaborative) performed deep longitudinal 
characterization of the Long COVID symptoms and trajectories in suspected and confirmed 
COVID-19 patients who reported illness lasting more than 28 days.13 Evaluating data from 3,762 
respondents to 257 survey questions, this analysis documented 205 phenotypic features 
associated with Long COVID. The symptoms most frequently reported after 6 months were 
fatigue, post-exertional malaise, and cognitive dysfunction. Patients who reported symptoms 
lasting for longer than six months following acute infection experienced an average of 14 
symptoms in month 7, and 86% of patients experienced relapses during the period assessed, 
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with exercise, physical or mental activity, and stress reported as common triggers. The diversity 
of the symptoms reported by Long COVID patients underscores the urgent need to understand 
the natural history of COVID-19 following the initial infection in order to manage medical care of 
affected individuals. 
 
Given Long COVID’s very recent emergence, no standard framework has yet been 
established for identifying and assessing associated symptoms or other clinical indicators. Most 
of the studies analyzed in the systematic review33 utilized a survey-based approach, meaning 
that they were able to analyze only symptoms identified a priori as concerns. These studies also 
varied in whether they included formerly hospitalized patients exclusively or a mixture of 
patients with mild, moderate, and severe cases of acute COVID-19. Long COVID can occur 
following either severe or relatively mild acute illness,37 and it has been suggested that the 
severity of acute illness affects the clinical course of Long COVID,32 as it does in SARS and 
MERS.38 Additionally, patients who are treated in the intensive care unit (ICU) would be 
assumed to be particularly likely to experience ongoing health challenges due to the well-
documented occurrence of post-intensive care syndrome (PICS).39 Several different frameworks 
have been proposed to describe Long COVID cases, without any clear criteria emerging about 
how to define the condition or how to stratify patients. This ambiguity presents a concern as 
more and more data is collected: as of the end of 2020, at least 239 papers and preprints about 
the post-acute effects of COVID-19 had been released, and approximately 20 additional papers 
become available each month.40 These papers do not conform to a single definition of Long 
COVID and do not evaluate consistent symptoms or markers of the disorder (or constituent 
disorders). In addition, the differences between the common symptoms as identified in a 
systematic review of the literature33 compared to the patient-led assessment13 indicates that 
current research on Long COVID may fail to address the full diversity of and even the most 
significant symptoms identified by patients with lived experience of Long COVID. Additionally, 
because proactive self-report is an important component of the patient-led research 
collaborative, symptoms and experiences of persons with low access to and uptake of 
technology may be under-represented in Long COVID studies thus far.  
 
In order to develop clinical management strategies to prevent or mitigate Long COVID, it 
will be essential for studies to use a unified definition of Long COVID and its subforms so that 
data from different studies can be integrated to provide the foundation for robust statistical 
inferences about risk factors for the development of Long COVID, as well as the natural history 
and response to treatments. Additionally, it is essential that survey-based research efforts to 
investigate Long COVID operate from a framework that addresses the symptoms most common 
among and most debilitating to Long COVID patients. A rigorous framework for evaluating Long 
COVID will also help to elucidate the organ systems involved in the disease and its sub-forms; 
such a framework could help to distinguish for example pulmonary versus cardiovascular 
syndromes and whether these are interrelated.. In this analysis, we present methodologies, 
findings, and perspectives related to the extraction of data from the literature, from an extensive 
patient survey, and from the NCATS N3C Data Enclave (covid.cd2h.org/enclave) to provide 
guidance towards defining and identifying symptoms and patient variables that must be 
considered while designing and developing studies of Long COVID. Given that Long COVID is 
poised to produce an additional public health crisis on top of the COVID-19 pandemic,36 rapid 
harmonization of existing data and the integration of this information into new efforts to 
characterize Long COVID will be the critical next steps in responding to this looming threat. 
Methods 
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Literature Review 
In order to explore how Long COVID is currently being characterized and reported, we 
conducted an exploratory landscaping review of the literature. The results of this search will 
inform a future, more systematic review of this topic. In addition to searching PubMed 
(MEDLINE), we included searches of specialized databases (e.g.,CoronaCentral; WHO Global 
Literature on Coronavirus Disease) and relied on expert recommended key articles, with 
snowball techniques to find similar studies. Both published articles and preprints were included 
for abstraction. The questions we explored in the review were: for observational studies of Long 
COVID, how are studies characterizing Long COVID, and what outcomes are reported and/or 
associated with this syndrome? In addition we explored whether any COVID-specific measures 
or tests have been developed or validated, whether any patient subgroups or medical 
specialties report unique signs or symptoms, and what patient-reported and patient-centered 
outcomes were reported (Supplemental Table 1). While specific Inclusion and Exclusion 
criteria were not developed, we did exclude papers discussing only rehabilitation therapy, 
mortality or hospitalization, as these were not outcomes specific enough to Long COVID. 
 
The newly emergent nature of Long COVID and lack of definition complicate traditional 
search methods. Each study abstracted was analyzed to identify the relationship of participant 
recruitment in the study to formal definitions of Long COVID that have been proposed. This 
analysis required evaluating how the duration of long-term symptoms was defined relative to the 
acute illness and whether patients were selected or stratified based on variables related to 
clinical course. Due to the proposed definitions at the time of analysis, the variables considered 
were: definition of onset of disease course (e.g., diagnosis, positive test, hospitalization), time 
elapsed since onset (as defined in each manuscript), patient-reported symptoms or clinical 
measures assessed, and tests or measurements reported or developed. 
Formal Definitions Used for Comparison 
Long COVID can be broadly defined as delayed recovery from an episode of COVID-19 
and is characterized by lasting effects of the infection, e.g., persistence of symptoms or onset of 
new chronic diseases, for far longer than would be expected.41 Although no firm criteria have 
been established to define the post-acute period or sub-categories within Long COVID, several 
sets of guidelines have been proposed for the classification of COVID-19-related disease 
phenotypes, and these criteria were compared to the definitions used in the literature. For 
example, a recently proposed public health framework classifies SARS-CoV-2-related disease 
into three categories.42 The first is acute COVID-19, or the disease most commonly associated 
with acute SARS-CoV-2 infection. The second category includes Multisystem Inflammatory 
Syndrome in Children (MIS-C) and in adults (MIS-A), a less common presentation of SARS-
CoV-2 infection characterized by hyperinflammation that can appear 4-6 weeks after viral 
infection.43 The third category describes late sequelae.42 In terms of defining study cohorts, 
adherence with this definition would therefore require a clinical diagnosis, rather than a SARS-
CoV-2 test alone, in order to distinguish MIS-C/A and COVID-19.  
 
Other frameworks break down the “late sequela” category into subtypes depending on 
either timing or disease natural history. For example, the United Kingdom’s National Institute for 
Health and Care Excellence’s guideline on long COVID provides two definitions of postacute 
COVID-19: (1) ongoing symptomatic COVID-19 for people who still have symptoms between 4 
and 12 weeks after the start of acute symptoms; and (2) post-COVID-19 syndrome for people 
who still have symptoms for more than 12 weeks after the start of acute symptoms.44 Similarly, 
PACS has been defined operationally as extending beyond three weeks from the onset of first 
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symptoms, and the term chronic COVID-19 has been proposed to refer to PACS cases where 
symptoms extend beyond 12 weeks;37 these PACS definitions are consistent with the virological 
data available thus far.45  
 
However, other criteria recommend defining the post-acute period as starting once a 
patient is discharged from inpatient acute care for those hospitalized longer than three weeks.45 
Some authors go further and subdivide Long COVID into three groups: 
1. patients who have experienced severe COVID with ARDS and experience long-term 
respiratory symptoms dominated by breathlessness; 
2. individuals with milder initial disease who were not necessarily hospitalized during the 
acute infection but but who present with a multisystem disease with cardiac, 
respiratory, or neurological manifestations of end-organ damage; and 
3. people who have persistent fatigue and other symptoms but with no evidence of 
organ damage.46 
Terminological Extraction from the Literature 
We reviewed patient-reported symptoms reported in the literature (or caregiver-reported 
symptoms in the case of one pediatric study47) and created a table row for each symptom in 
each publication. We then used a Python script to extract symptoms; . symptoms remained 
exactly as described in the manuscripts except to adjust for capitalization, punctuation, plurals 
(e.g., headache versus headaches), spelling in British versus American English (e.g., dyspnoea 
versus dyspnea), and to standardize labels assigned to specific measures. The identifiers for 
specific assessments used were as follows: FLU-PRO for InFLUenza Patient-Reported 
Outcome,48 EQ-5D-5L for the 5-level EQ-5D,49 EQ VAS for the EQ visual analogue scale,49 and 
mMRC Dyspnea Scale Scores for Modified Medical Research Council Dyspnea Scale Scores.50 
We tabulated the relationships between publications and the symptoms they reported; we then 
manually mapped symptoms to one or more body systems and visualized the result using a 
Sankey diagram (Figure 1). 
Ontological Coding of Literature and a Patient Survey  
The Human Phenotype Ontology (HPO) provides a standardized vocabulary of over 
15,000 terms to describe phenotypic abnormalities observed in human disease.51 In our review 
of the literature, we identified studies that also contained a description of the counts of affected 
individuals who displayed specific phenotypic features. We manually curated the mappings 
between literature-reported signs and symptoms and HPO terms. Overall, 141 unique 
symptoms were identified of which 80 terms were curated from the originally extracted literature 
terms, and 112 terms were captured from the both of the patient-led survey 
questions/answers.13,52 These are available in Supplemental Table 2.  
Cohort Selection 
We performed analysis of electronic health record (EHR) data in the N3C Secure Data 
Enclave (covid.cd2h.org/enclave) with the intention of identifying unique healthcare utilization 
patterns among COVID-positive patients that may differentiate them as Long COVID patients. 
To achieve this, we looked for patterns found only in COVID-positive patients compared to 
COVID-negative controls. Some patients were expected to be COVID-positive but non-Long 
COVID, so this analysis was expected to distinguish at least three categories: COVID-positive 
and Long COVID, COVID-positive and non-Long COVID, and COVID-negative.  
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We define COVID-positive as any non-deceased patient in the N3C enclave with an 
ICD-10-CM diagnosis code for COVID (U07.1) or a positive PCR, antibody, or antigen test for 
COVID (n = 905,592). We define COVID-negative as any non-deceased patient in the N3C 
enclave with at least one negative PCR, antibody, or antigen test for COVID who is not also in 
the positive group (n = 2,473,206). We then further narrow the set of patients whose data is 
used for analysis in the following ways: 
• We require all patients to have at least one year of history with their contributing health 
care system. 
• For COVID-positive patients, we require that at least 90 days have passed since their 
COVID index date (minimum date of diagnosis or positive test). 
Applying these restrictions resulted in a case (positive) cohort of 314,237 patients, and a control 
(negative) cohort of 1,917,935 patients. 
 
We then employed the R package MatchIt53 to perform nearest-neighbor propensity 
matching on the positive and negative patients, at a ratio of 2:1 (control:case). The following 
factors were used in matching: age, sex, race, site (exact match required), and comorbid 
conditions (diabetes, chronic kidney disease, congestive heart failure, peripheral vascular 
disease, chronic pulmonary conditions). A patient was defined as having a comorbid condition if 
they had two or more ICD-10-CM codes equating to that condition in their EHR data. Two sites 
(representing 14,222 cases) were removed from the matching process due to a significant 
amount of missing data required for matching. Additionally, 2,311 cases were dropped because 
they were not able to be matched with two controls at their same site. This resulted in a final 
case set of 297,704 patients, and a final control set of 595,408 patients. The case set was 
further split into two groups: cases who were hospitalized for COVID (n = 51,903) and patients 
not hospitalized for COVID (n = 245,801). 
 
We opted to model COVID-related healthcare utilization patterns among the cases and 
controls by counting occurrences of COVID- and Long COVID-related diagnoses (See “Long 
COVID Concept Sets,” below) for each patient before and after their COVID index date. 
(Controls were assigned their matched case’s index date.) Diagnosis occurrences were counted 
across an equal time period before and after the patient’s COVID index, based on how many 
days have passed since the COVID index. We ignored diagnoses occurring in a “buffer” period 
of 60 days before and after the COVID diagnosis, to attempt to differentiate “post-COVID” from 
active COVID. 
 
 After representing the data as a matrix of pre- and post-diagnosis conditions, we applied 
nonnegative matrix factorization in order to extract conserved co-occurring sets of diagnoses 
that best represent the cohort. The result of this step is a data-driven representation of which 
sets of diagnoses occur together. We then compared the change in frequency of these 
diagnoses before and after COVID to identify potential signatures of Long COVID. 
Long COVID Concept Sets 
Concept sets were obtained by mapping a subset of the manually curated HPO 
concepts to OMOP concept identifiers within the Conditions domain (Supplemental Table 3). 
These mappings were obtained using OMOP2OBO.54 OMOP2OBO is an algorithmic framework 
designed to generate clinically meaningful mappings between Open Biomedical Ontologies 
(OBO) and standard clinical terminologies in the OMOP common data model. Using version 
1.0.0 of the mappings, each of the HPO concepts were processed and all reasonable matches 
returned. HPO concepts unable to be mapped using OMOP2OBO were manually mapped using 
Version 1.12.0.6.210309.1608 of the Athena - OHDSI Vocabulary Repository,55 which at the time 
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of mapping was populated with OMOP Vocabulary version: v5.0 26-FEB-21. All manual 
mappings were discussed with one or more professional ontologist and/or clinical phenotyping 
experts. Upon ingestion into the N3C Enclave, HPO concept sets were extended to include all 
descendant concepts for each included OMOP concept identifier. Each of the completed 
concept sets received an additional round of review by clinical domain experts within the 
Enclave prior to use in classifying the cohorts as described above. 
Results 
Literature Review 
The analysis of 39 studies revealed a variety of criteria were used to identify and 
evaluate patients with post-acute COVID-19 sequelae. With nearly as many definitions as 
studies, it is clear that there is no agreement on the definition of Long COVID (Figure 1). 
Studies differed in how they referred to the phenomenon studied. Some referred to it as Long 
COVID or using a similar term such as post-acute COVID-19 syndrome, whereas others 
discussed the clinical course or patient recovery without mentioning Long COVID specifically. 
These definitions fell roughly into four categories (Table 1). Most studies refer to their patient 
recruitment in terms of recovery (e.g., “COVID-19 survivors”56 or “discharged COVID-19 
patients”57) or clinical course (e.g., “medium- and long-term consequences”58 or “delayed return 
to usual health”59). A number of studies did refer to their participant groups using terms like 
“Long COVID”,13,60–68 “post-acute COVID-19”,69,70 “post-COVID syndrome”,71 or “post-acute COVID-
19 syndrome”,72 but these terms were not standardized among studies. A few studies46,60 
acknowledged the proposed distinction at 12 weeks post-infection between post-acute COVID-
19 and chronic COVID-19,37 but otherwise the definitions used typically did not refer to any 
proposed operationalizations of Long COVID. Therefore, while operational definitions of the 
constituent components of Long COVID have been proposed,37,42,44 reviewing the Long COVID 
literature revealed that they are rarely used when describing cases or identifying study cohorts. 
 
Table 1. General definitions of Long COVID used in the literature. The 39 papers and preprints reviewed 
could be binned into four general categories in their operationalizations of Long COVID. 
Characterization of Long COVID # of studies reporting References 
COVID-19 Clinical Course (& Related) 16 
14,32,46,47,57,59,73–82
 
COVID-19Recovered Patients (& Related) 8 
56,58,83–88
 
Long COVID 10 
13,60–68
 




Moreover, the existing operational definitions of Long COVID differ in important ways, 
many of which are not differentiated by existing studies. For example, one framework46 
subdivides Long COVID patients into three groups based on whether their long-term symptoms 
are primarily respiratory in nature following severe COVID-19 with ARDS, whether they present 
with a multisystem disease with cardiac, respiratory, and/or neurological manifestations of end-
organ damage, or whether their primary symptoms are persistent fatigue and other symptoms 
that do not necessarily indicate organ damage.46,89 In the literature analyzed, this definition was 
never used to define cohorts. Many studies included patients with acute infections that varied in 
their severity, including both inpatient and outpatient convalescents (e.g., 82,85). Additionally, of the 
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studies available thus far, data directly assessing organ damage is rarely collected, and the 
concept of organ damage itself has not been operationalized in this context.  
 
Other efforts to define Long COVID identify the severity of the acute phase as an 
important consideration in determining the onset of the post-acute phase. Specifically, for 
individuals hospitalized for more than three weeks following symptom onset, some definitions 
identify the post-acute period as starting once the patient is discharged from inpatient acute 
care.45 In the literature surveilled, most studies recruited and assayed patients based on time 
elapsed from a COVID-19-related milestone, but what the milestone was varied widely. Some 
studies use the date of diagnosis or positive test, others the onset of symptoms, others hospital 
discharge, and others by even broader criteria (e.g., patients with suspected or confirmed 
COVID-19 in the past). Many studies used a relatively precise window for patient assessment 
(e.g., 30 to 45 days after diagnosis65 or 14 to 21 days after symptom onset59), while others 
included participants at various distances from acute SARS-CoV-2 infection under the umbrella 
term of Long COVID.46 In the latter case, these patients could fall under either the Long COVID 
(PACS) or chronic COVID-19 definitions if using a 12-week cutoff.37,44 Because the relationship 
between infection, symptoms, and viral clearance occupies a wide distribution,62,90,91 this 
heterogeneity among and sometimes within studies could introduce significant variability in 
disease course within and among patient cohorts. 
 
 
Figure 1. Heterogeneity of reported phenotypes for post-acute COVID-19 sequelae. Clinical and 
patient-reported symptoms, time course, and patients counts were extracted from the literature (see 
Supplemental Table 1. The author and year associated with each publication is provided in the first 
column. The second column indicates the exact phenotypes reported in each study, corresponding to 
symptoms and clinical indices. Symptoms and indices are categorized into phenotype groups. Most of the 
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142 symptoms or indices reported were unique to a single study. Examples of terms used are magnified 
in the pull-out. Supplemental Table 1 contains the literature extracted.  
 
Finally, studies varied wide in the terminology used to describe patient-reported 
symptoms. Comparing symptoms described across the literature reviewed revealed 142 unique 
terms related to symptoms, including scales used to assess symptom profiles (e.g., the 
University Of California San Diego Shortness Of Breath Questionnaire) or other dimensions of 
recovery (e.g., 5-level EuroQoL 5-Dimensions for quality of life) (Figure 1). The most commonly 
evaluated symptoms were fatigue (15 studies), dyspnea (11 studies), chest pain (11 studies), 
and headache (8 studies). In many cases, studies assessed similar symptoms but differed in the 
nomenclature used. For examples, the studies analyzed included a mixture of reports of 
ageusia,32,52,79 anosmia,32,52,79,82 anosmia/ageusia,76 loss of smell,59,68 loss of taste,59 loss of smell and 
taste,66 loss of smell or taste,65 and loss of smell and/or taste.77 While in many cases there are 
parallels among studies (e.g., studies reporting anosmia and loss of smell are likely to be asking 
the same or similar questions of patients), the lack of a strict definition prevents straight-forward 
symptom matching across analyses. Further, there seemed to be limited surveying of 
neurological and systemic symptoms in some cases, hence the absence of common symptoms 
like cognitive dysfunction or "brain fog", sensorimotor symptoms, and post-exertional malaise. 
This is where standard use of a full terminology such as HPO would be useful to create 
expressive and consistent meaning across studies. 
 
Therefore, the literature indicates that at present there is little consistency among studies 
in definitions of Long COVID, including the symptoms analyzed. Few studies use terminology 
with a proposed, narrow-scope definition such as Greenhalgh and colleagues37 definitions of 
PACS and chronic COVID. Instead, studies typically define a period of time to investigate 
symptoms agnostic of how this factors into the broader conversation on the disease. The 
exception is studies that state they are investigating Long COVID, which use a wide variety of 
definitions. The same is true for post-acute COVID-19 or post-COVID syndrome, which are 
typically not explicitly tied to working definitions or explicit disease phenotypes. Among studies, 
patient inclusion criteria can be based on any number of relevant milestones from the acute 
phase, and only a subset of studies separate patients based on the severity of disease they 
experienced in the acute phase. Finally, no standardized terminology is used for patient-
reported symptoms, and studies often report symptoms using similar but non-identical 
terminology. Thus, the literature analysis suggests significant heterogeneity among studies with 
respect to how they define cohorts of interest and analyze the experiences of patients 
experiencing Long COVID. 
Ontological Analysis of Literature 
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Figure 2. Average frequency of constitutional symptoms (specific terms descending from HP:0025142, 
Constitutional symptom, which is defined as a symptom or manifestation indicating a systemic or general 
effect of a disease and that may affect the general well-being or status of an individual). Frequencies are 
given separately for the 19 researcher-led studies and two patient-led studies. 
 
 
From the results of the above exploratory review, candidates were selected to comprise 
a cohort of studies for further abstraction and analysis. Because of the poor reporting by and 
heterogeneity within our initial set of literature, the numbers of studies in this cohort is much 
smaller than the set of studies summarized above. This highlights the need for improved quality 
and reporting of even small cohorts. Details such as the specific definition used to identify 
patients with COVID-19 (e.g., a PCR test versus a clinical diagnosis), hospitalization status 
(outpatient versus inpatient versus ICU), the severity of illness represented among patients in 
the cohort, and the number of patients presenting with each symptom or other clinical measure 
are important to efforts to compare results across studies. 
Here, 21 studies, including 20 published studies14,47,52,56,58,59,63,66,72,73,75–77,79,92–97 and one preprint,13 
were chosen for the in-depth phenotypic analysis using HPO. A total of 154 different phenotypic 
abnormalities could be encoded using HPO terms. Table 3 provides an overview of the most 
commonly observed abnormalities in four major categories, and Supplemental Table 2 
contains information about all 154 terms. The studies investigated and reported the phenotypic 
features in a very heterogeneous fashion. Only one abnormality, dyspnea (shortness of breath), 
was reported in every study. 95 terms were reported on only a single study. 
 
Table 3. Summary of selected phenotypic manifestations in 21 studies (including two patient surveys) in 
post-acute COVID-19. 
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System HPO Term Studies (n) Frequency 
Nervous System 
Diminished ability to concentrate 
(HP:0031987) 6 2872/3987 (72.0%) 
Insomnia (HP:0100785) 4 2646/3872 (68.3%) 
Short term memory impairment 
(HP:0033687) 1 2438/3762 (64.8%) 
Impaired executive functioning (HP:0033051) 1 2166/3762 (57.6%) 
Cognitive impairment (HP:0100543) 1 3203/3762 (85.1%) 
Paresthesia (HP:0003401) 1 1852/3762 (49.2%) 
42 HPO terms with frequency < 50% 1-19 0.6% - 49.2% 
Respiratory System 
Dyspnea (HP:0002094) 21 5144/8650 (59.5%) 
Nonproductive cough (HP:0031246) 2 2498/3942 (63.4%) 
22 HPO terms with frequency < 50% 1-17 0.7% - 40.4% 
Constitutional 
Symptom 
Fatigue (HP:0012378) 23 7829/10321 (75.9%) 
Chest tightness (HP:0031352) 5 3877/6669 (58.1%) 
Post-exertional malaise (HP:0030973) 1 3350/3762 (89.0%) 
13 HPO terms with frequency < 50% 1-16 3.0% - 45.6% 
Cardiovascular 
Tachycardia (HP:0001649) 2 2368/4300 (55.1%) 








Transforming the HPO codesets  
For the EHR analysis, we focused on 77 HPO annotations commonly used in the 
literature. Of these, 76 were successfully mapped to at least 1 OMOP concept identifier within 
the Condition domain (min=1, max=84, median=3). The unmapped HPO concept, increased 
circulating brain natriuretic peptide concentration (HP:0033534), could not be reasonably 
aligned to an OMOP concept identifier within the Condition domain. When expanding each 
OMOP concept identifier to include its descendant concepts, the total number of OMOP 
concepts used was 7,542 (4,694 unique) and the median number of OMOP concept identifiers 
mapped to each HPO codeset was 16. The largest HPO codeset sets were paresthesia 
(HP:0003401; n=1,606 concepts), pain (HP:0012531; n=1,399 concepts), skin rash 
(HP:0000988; n=505 concepts), and anxiety (HP:0000739; n=355), which was not unexpected 
given the variability in the clinical presentation (e.g., severity, duration, and location) of the 
conditions associated with these concepts. 
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Defining EHR phenotypes, including/excluding HPO codesets 
 
Figure 3. Schematic illustrating the method used to identify patients for Long COVID analysis, mapping of 
these patients’ data to HPO via OMOP2OBO codesets, and looking for patients with HPO phenotypic 
features from the mapped data to define a potential Long COVID cohort. 
 
The 297,404 patients in the final case group represent the pool of patients from which 
we have the potential to detect Long COVID (Figure 3). 85,912 of these patients had at least 
one instance of the identified HPO codes in their post-COVID period (and thus may be more 
likely to have Long COVID). Slightly more than half of these patients showed an increase in 
HPO codes after their diagnosis, with the largest shifts observed in hospitalized patients. 
Reduced dimension representation of the data suggested that HPO groups related to pain, 
anxiety/depression, and respiratory ailment. Further analysis will be required to determine which 
clusters of HPO codes are potentially indicative of Long COVID, allowing us to further stratify 
patients. 
Table 4. Defining a cohort of potential Long-COVID patients. Comparing characteristics of non-
deceased COVID patients with >= 1 year pre-COVID longitudinal data and >=90 days since COVID 
diagnosis (column 1); and COVID patients with >= 1 year pre-COVID longitudinal data, >=90 days since 
COVID diagnosis, and an instance of a Long COVID phenotypic feature >= 60 days after their COVID 





All qualifying cases with Long 








 Female 119,843 (56.6) 55,478 (64.6) p 
<0.001  Male 91,930 (43.4) 30,425 (35.4) 
 Unknown <20 (0.0) <20 (0.0) 
Age  mean (SD) 44.62 (21.12) 49.84 (19.77) p <0.001 
Race 
 Asian 5,401 (2.6) 1,954 (2.3) 
p 
<0.001 
 Black 35,241 (16.6) 17,634 (20.5) 
 White 135,563 (64.0) 52,570 (61.2) 
 Other/Unknown 35,587 (16.8) 13,754 (16.0) 
Ethnicity  Hispanic/Latino 26,896 (12.7) 11,192 (13.0) p 
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(75.5) 63,829 (74.3) 
<0.001 
 Other/Unknown 25,053 (11.8) 10,891 (12.7) 
Comorbidities 
(Pre-COVID) 
 Diabetes 22,169 (10.5) 16,270 (18.9) p <0.001 
 Kidney disease 11,385 (5.4) 9,308 (10.8) p <0.001 
 Heart failure 6,482 (3.1) 6,074 (7.1) p 
<0.001 
 Pulmonary 





The analyses described above demonstrate the heterogeneity both in symptoms 
associated with Long COVID and in assessments and definitions used to study Long COVID 
present in the literature as well as an EHR-based approach for identifying natural language data 
associated with potential Long COVID patients available in N3C.  
Sources of Variance in Defining Long COVID 
The literature review revealed a wide variety of terms used in describing patient cohorts 
used for studies of symptoms occurring after the acute phase of COVID-19. Most studies do not 
seek to assign their patients to a particular diagnosis or operational definition, although several 
referred to the definition from Greenhalgh et al. (2020)37, which is consistent with the virological 
data available thus far.45 There are a number of dimensions in which the existing literature varies 
in efforts to operationalize definitions of Long COVID. These differences are expected to vary in 
their effects. An important goal in the next phase of Long COVID research needs to be 
identifying the most critical considerations in defining patient cohorts. 
Ambiguity in Defining the Acute Infectious Period 
 
Long COVID is typically defined based on an elapsed acute infectious period, but at 
present, the relationship between the timing of COVID-19 symptoms relative to SARS-CoV-2 
infection is not well understood.98 One early study examining viral load in hospitalized patients 
reported that viral shedding continued for at least 28 days following symptom onset in some 
patients.99 Another study reported that the median period between a patient’s first positive PCR 
test and cessation of viral shedding was 17 days and that up to 70% of patients were still 
symptomatic when their viral shedding ceased.90 However, viral shedding (e.g., the presence of 
detectable SARS-CoV-2 virus in samples such as nasopharyngeal swabs) does not necessarily 
indicate the presence of replication-competent viral particles. Viable viral particles have been 
detected from 6 days prior to up to 9 days after symptom onset.100–102 Patients have also been 
observed to test positive by PCR following a negative test,103–105 but the virus could not be 
cultured. Both asymptomatic and symptomatic patients with retest-positive COVID-19 have 
been identified.103 Even in individuals whose nasopharyngeal swabs produce negative PCR 
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results, some test positive for SARS-CoV-2 in the intestine.106 These results therefore suggest 
that after the initial infection, patients shed non-infectious, degraded viral particles.104  
 
In Long COVID, this relationship is further complicated by the fact that many patients 
who report symptoms of Long COVID lack a formal diagnosis. Due to the scarcity of tests in 
many places at the beginning of the COVID-19 pandemic, many patients who had suspected 
COVID-19 were never tested for the presence of the SARS-CoV-2 virus.107 In current studies, 
there is significant variability in the inclusion/exclusion criteria used for patient recruitment in 
terms of COVID-19 test status. While some studies require a positive test, others recruit patients 
with either a confirmed or suspected diagnosis (Table 1). Furthermore, some studies fail to 
specify whether the tests used for selecting patients are PCR-based, serum antibody based, or 
a mixture of the two. This distinction is important because the rate of false positives and false 
negatives is much higher in the antigen/antibody tests,108–111 meaning error rates may vary among 
studies. This limitation presents challenges for clinicians in determining the likelihood that 
patients with non-specific symptoms have Long COVID, and also presents difficulties for large-
scale efforts to characterize symptoms associated with COVID-19 and Long COVID.32,112 
Initial EHR characterization of a potential Long COVID Patient Cohort 
 There is not currently an ICD-10-CM diagnosis code for long-COVID; thus, our ability to 
find patients with long-COVID using structured EHR data is limited. Lacking an ICD-10-CM 
code, we utilized the HPO terms curated from the literature and patient surveys to refine the 
potential cohort based by looking for patients with at least one of these specific HPO terms. The 
patients characterized in Table 4 represent a base population from which EHR analysis may be 
able to identify Long-COVID. These are patients who had COVID, have enough pre-COVID 
longitudinal data to enable us to compare their healthcare utilization pre- and post-COVID, and 
have had enough time pass since their COVID diagnosis to be out of the acute phase.  While 
we cannot say with certainty that the patients who reported one or more long-COVID symptoms 
have long-COVID, as shown in Table 4, the characteristics of this group are significantly 
different from those cases lacking a reported symptom. This cohort would be an ideal group for 
deeper phenotyping, leveraging additional data sources such as features derived from free-text 
notes in the EHR, imaging, or claims data. 
Related and Concurrent Disorders 
One major issue arising from the challenges to determining whether a patient has 
recovered from COVID-19 is that post-acute symptoms can also arise from different etiologies. 
One potential source of ambiguity come from PICS, which describes new or worsening 
cognitive, psychological, and physical limitations experienced by patients following discharge 
from an intensive care setting.39 Some impairments have been observed to persist for years after 
discharge, including pulmonary effects that are exacerbated by intubation and can persist for 
five years or longer and decreased ability to conduct activities of daily living that can last for 1-2 
years.113 Therefore, symptoms of PICS could potentially be conflated with symptoms of Long 
COVID in patients who were ventilated and/or treated for COVID-19 in the ICU. Another 
possible source of long-term symptoms is the treatments used during the acute illness. In 
SARS, some of the most common post-acute sequelae are thought to be caused by treatment 
with corticosteroids.27,28 Therefore, the care received during the acute phase of the illness holds 
the potential to influence the clinical course of recovery, and therefore should be considered in 
efforts to identify signifiers of Long COVID. 
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While COVID-19 is a complex and heterogeneous multisystem illness, patients infected 
with SARS-CoV-2 can also develop distinct illnesses. A multisystem inflammatory illness has 
been observed in children and in some adults following acute infection with SARS-CoV-2. This 
syndrome, called multisystem inflammatory syndrome in children (MIS-C) and in adults (MIS-
A),43 is characterized by hyperinflammation and can begin subsequent to host clearance of 
active SARS-CoV-2 infection.42 This condition is rare, with estimates of two in every 100,000 
children in a descriptive analysis of MIS-C cases in New York State.114 This report also identified 
a median of 21 days from when children experienced COVID-19 (or an illness likely to be 
COVID-19) and when they were admitted to the hospital for MIS-C and that they were 
hospitalized for a median of 6 days.114 MIS-A has been reported only very rarely, with only 30 
known cases as of October 2020.115 The importance of distinguishing the natural history of MIS-
C/A from that of COVID-19 has been highlighted in some efforts to operationalize definitions of 
Long COVID,42 but at present, MIS-C/A is not widely discussed in the Long COVID literature, 
even though it too manifests in the post-acute phase of infection. 
 
Similarly, preliminary findings suggest that patients with SARS-CoV-2 infection are at 
risk for chronic illnesses associated with post-viral sequelae. One example is that some 
presentations of Long COVID bear a resemblance to CFS, another chronic condition that is 
often triggered by a viral infection.20 The broad relationship between these known sequelae of 
viral infections and the specific pathogenesis of SARS-CoV-2 remains to be identified, although 
some mechanisms have been proposed116. In terms of characterizing the long-term sequelae of 
SARS-CoV-2 infection, they may introduce additional ambiguity regarding the specific outcomes 
associated with this particular virus compared to viral infections more broadly. 
Organ Damage 
One definition of Long COVID46 specifically highlights the potential importance of 
distinguishing long-term symptoms arising from organ damage from those arising from other 
etiologies. Given that a large number of Long COVID patients suffer from fatigue, which is 
associated with other post-viral syndromes but for which there are limited treatment options,20 
identifying whether and when Long COVID patients have sustained long-term organ damage 
may provide additional options for treatment and understanding of the disease. However, few 
studies of Long COVID to date have conducted analyses elucidating the presence or extent of 
organ damage. Many assessments to collect evidence of long-term organ damage are 
intensive, meaning that their feasibility may vary with the strain on hospitals during the course of 
the COVID-19 pandemic. However, preliminary investigations of a number of organ systems 
have identified organ damage in Long COVID patients. These findings are also important 
because they highlight the possibility of asymptomatic Long COVID patients, who could sustain 
organ damage due to the SARS-CoV-2 virus that does not immediately present with symptoms. 
Therefore, an improved understanding of organ damage as an outcome of acute COVID-19 or 
as a long-term sequelae of the SARS-CoV-2 virus may present new options for patients 
experiencing persistent symptoms or elucidate new information about how the SARS-CoV-2 
virus interacts with a range of organ systems.  
Post-AKI CKD, Diabetes, and Long COVID Syndrome 
During acute SARS-CoV-2 infection, diffuse endothelial injury, leads to end organ 
perfusion abnormalities and microthrombi. This reduced perfusion contributes to acute kidney 
injury (AKI), and possibly to new-onset diabetes.117–119 AKI, especially moderate/severe AKI, is a 
risk factor for the development of chronic kidney disease (CKD).120 Apoptosis, maladaptive 
repair, and fibrosis have been postulated as mechanisms involved in the transition from AKI to 
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CKD.121 The kidney is an organ of interest in Long COVID because acute SARS-CoV-2 infection 
is associated with kidney injury.122,123 SARS-CoV-2-associated microvascular injury may cause 
perfusion abnormalities within the pancreatic islets, skeletal muscle, heart and or brain. In the 
islet, for example, microcirculation is essential for both glucose sensing and insulin secretion; 
abnormal islet capillary architecture and fragmentation contributes to beta cell dysfunction in 
type 1 and type 2 diabetes.124 Diabetes is a known contributor to CKD. Both CKD and diabetes 
are major risk factors for cardiovascular disease (CVD)125 and long term disability, which may 
overlap with the complicated picture of PASC.126  
An unpublished investigation and a complementary published analysis provide evidence 
highlighting the relevance of kidney damage to medium-to-long COVID-19 outcomes. A pilot 
investigation (unpublished) was conducted on a subgroup of 35 COVID-19 AKI survivors who 
were admitted at Stony Brook University Hospital, NY between March and June 2020 and 
subsequently followed in a “Post-AKI COVID clinic.” Patients were observed at a 6-month 
follow-up to have a high incidence of persistently reduced renal function after moderate/severe 
AKI in the setting of hospitalization with COVID-19. De novo or progressive CKD was noted in 
25.7% & 74.3% of cases based on estimated glomerular filtration rate (eGFR) + serum 
creatinine (SCr) and only SCr measures, respectively. A second study in a Swedish cohort127 
similarly investigated kidney dysfunction following acute illness. In a group of 60 ICU patients 
admitted for COVID-19 infection, they found that inpatient AKI severity was associated with 
higher CKD stages at 3- to 6-month follow up.127 They found no differences between patients 
with CKD progression compared to those without progression in terms of demographics, 
comorbid conditions, or ICU admission characteristics.127 Similarly, in the unpublished study, 
neither inpatient AKI recovery nor a history of CKD prior to admission were associated with 
worsening renal function at follow up. Both of these analyses are limited due to a small sample 
size. Ongoing study at Stony Brook’s Post-AKI COVID clinic will include additional patients and 
longer follow-up and therefore should provide a more accurate estimate of CKD risk. It is not yet 
known whether inadequate renal repair after severe injury or persistence of SARS-Cov-2 in the 
kidney drives post-AKI CKD in COVID-19.  
While AKI is an established independent risk factor for CKD,128 this association has not 
yet been extensively explored in the setting of COVID-19, given that the virus has been 
circulating for just over a year at this time and studies so far have mostly reported the 
persistence of renal dysfunction (AKD) at time of hospital discharge.129,130 Persistent organ 
damage is now considered part of the Long COVID syndrome,45,131 and kidney disease should be 
considered part of this syndrome. While these two studies are among the first reporting this 
association, further multi-center studies with larger sample sizes and with pathology data are 
needed to further analyze the relationship between AKI and development/progression of CKD in 
COVID-19. 
Neuroimaging in Analyses of Long COVID 
A variety of neuroimaging findings have been reported in COVID-19 patient populations, 
and efforts to better understand pathophysiologic origins and neuroanatomical correlates are 
ongoing. A number of studies have been carried out to characterize COVID-19 neuroimaging 
findings and associated neuropsychiatric symptoms, e.g. 132–135. There have been a few focused 
imaging studies that attempt to dissect neuroimaging correlates associated with specific 
symptoms; for instance, olfactory bulb abnormalities were characterized in an MR imaging study 
of COVID-19 anosmic patients.136 One study comparing 35 Long COVID patients to 44 controls 
found significant hypometabolism in the brain, including the olfactory gyrus, right temporal lobe 
(including the hippocampus and amygdala), the bilateral pons/medulla brainstem, and the 
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bilateral cerebellum; notably, the clusters of hypometabolism were correlated with patient 
symptoms, including hyposmia and anosmia, memory and cognitive impairment, pain, and 
insomnia.137 There have also been additional suggestions that brainstem dysfunction might be 
involved in a variety of COVID-19 clinical manifestations. For instance, Yong138 cites a number of 
autopsy studies to support this hypothesis.139,140  
Autopsy as a Means to Diagnose Long COVID 
Autopsy analysis is an important method to obtain insights into the pathology associated 
with COVID-19 and the presence of the SARS-CoV-2 virus in diseased tissues. Kidney tissue 
provides a good example of the importance of autopsy analysis. AKI is very common in patients 
hospitalized with COVID-19 and is a major risk factor for mortality.141–143 Kidney autopsies or 
biopsies in patients with Covid-19 related AKI do not generally reveal suggestions of direct viral 
cytotoxic effects such as nuclear, cytoplasmic inclusions or with extensive tissue necrosis and 
inflammation.144 Autopsy and kidney biopsy tissue studies have indicated that acute tubular injury 
is the most common pathologic finding Covid patients with AKI or proteinuria.145 Collapsing 
glomerulopathy and thrombotic microangiopathy are also been associated with Covid 19 AKI in 
autopsy and biopsy studies.145  
Multi-organ and especially renal tropism of SARS-CoV-2 has been observed in autopsy 
studies on COVID-19 patients. Puelles et al1 reported the presence of viral load and also viral 
RNA and proteins in the kidney using in situ hybridization and indirect immunofluorescence with 
confocal microscopy. In an autopsy study of 26 patients with COVID-19, Su et al.146 found 
clusters of coronavirus-like particles in the kidney tissue on electron microscopy and also 
detected positive immunostaining with SARS-CoV nucleoprotein antibody associated with injury 
patterns on light microscopy.146 Autopsy studies have also shown that SARS-CoV-2 infects and 
replicates inside pancreatic beta cells, reducing insulin-sensing functions of those cells.147 This 
direct infection of the pancreatic beta cells is likely a lead cause of metabolic dysfunction and 
glycemia after SARS-CoV-2 infection. The N3C database offers a unique opportunity to study 
glycemia before and after SARS-CoV-2 infection, as well as how new-onset diabetes may 
contribute to PASC effects on quality of life for both adults and children. 
In a review of brain autopsy studies, summarizing 24 studies with results from 149 
individuals chronic inflammation or neural changes typically associated with viral infections were 
found to be largely absent.148  Interestingly, in one recent study, megakaryocytes were found in 
cortical capillaries in 33% of brain autopsy cases examined.149 The authors thereof a) noted that 
this observation was consistent with other observers who have noted megakaryocytes150, 151 and 
b) suggest that these large cells could cause ischemic alternation in a distinct pattern and might 
be associated with COVID-19 neurological impairment.  
The timing of autopsy is likely to be important in efforts to detect whether SARS-CoV-2 
remains in tissue. In another study examining 42 postmortem samples of patients who died with 
COVID-19, no presence of SARS-CoV-2 was noted in analysis with immunofluorescence, 
electron microscopy or in situ hybridization of the kidney tissue.152 This study raised concerns 
about the method and timing of post-mortem tissue collection and processing, since a significant 
degree of autolysis was noted in the kidney tissue in this study.153 In a recent study of immediate 
(≤3 hours) post-mortem renal biopsies of 16 patients with COVID-19 and 5 control patients with 
sepsis, investigators reported that the presence nCoV2019 N-Protein was detected in proximal 
and distal renal tubules in 9 of 16 cases, out of which 6 of the 9 were confirmed by in situ 
hybridization. This finding supported the presence of SARS-CoV-2 in the kidney.154 However, 
SARS-CoV-2 E and N1/N2 genes were detected by RT-PCR of the kidney total RNA in only one 
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case, and classical viral inclusions were not detected via electron microscopy. Therefore, while 
autopsy can serve as an important tool in looking for the presence of SARS-CoV-2 in tissues 
and the associated pathology, the methodology used for autopsy is critical to providing accurate 
insights into disease patterns. 
COVID-19 and Quality of Life 
The circumstances surrounding infection with SARS-CoV-2 and the pandemic itself are 
likely to have a significant impact on patients’ health. In particular, psychosocial health, nutrition, 
and physical fitness may all be impacted by the broader societal response to SARS-CoV-2. 
Early in the pandemic, the WHO released recommendations to support psychosocial health in 
light of the pandemic (Mental health and psychosocial considerations during the COVID-19 
outbreak). Since then, many reports have indicated concern about a rise of psychosocial 
distress internationally.155–158 While unique psychological stressors are likely to affect patients who 
experience COVID-19 and especially those with more severe cases, the impact of a broader 
societal decline in psychological health (including addiction/substance abuse disorder) may be 
difficult to identify in studies that evaluate only COVID-19 patients with and without Long 
COVID. Similarly, viral infections can exacerbate pain and other chronic conditions,159 but these 
effects are not specific to SARS-CoV-2 even though they may appear that way depending on 
study design. Similarly, the conditions of the pandemic have reduced access to healthy food 
choices in some places160,161 and reduced opportunities for exercise.162 Social distancing also 
presents unique challenges to patients with substance use disorders; as loneliness and stress 
can make people more inclined to substance use.163,164 As governmental and societal responses 
to SARS-CoV-2 evolve, it is possible that quality of life and psychosocial reports from Long 
COVID patients may shift along with those of the population more broadly.165 
Research Response and Measurement Problems 
Because of the pandemic, there has been an incredible surge of research and a call for 
the surveillance of COVID-19 patients.166,167 Thousands of clinical trials are being registered, 
initiated and, in many cases, completed on COVID-19 treatment and prevention in the USA and 
across the planet.168 While this response is impressive, there are risks to rapidly planning and 
performing expedited clinical trials.169 For example, recent reviews of registered protocols have 
revealed methodologic flaws and a wide array of outcomes measures, particularly patient-
reported outcome measures (PROMs), being used,169–171 most of which have not been vetted for 
relevance to COVID-19 patients.172 Moreover, the lack of available terminological standards 
greatly impede the ability to compare studies. 
 
There are two obstacles to the design of clinical research in this area. First, there has 
not yet been any rigorous large-scale effort to characterize the constellation (incidence and 
breadth) of outcomes most important to Long COVID patients. Without this characterization it is 
not possible to design inclusion criteria for responsible clinical studies. A second and related 
obstacle is there have not yet been efforts to define the sets of core domains and outcomes for 
patients in future clinical studies. Heretofore the lack of uniformity in outcome measurement 
across clinical research creates multiple problems: it undermines the validity of this research, 
shows a lack of relevance to the patient perspective, and limits our ability to compare findings 
between studies or to pool data for meta-analyses.139,173 
 
In an effort to reduce heterogeneity in outcomes measured across clinical trials, and to 
improve the clinical monitoring of patients, the development of core domain sets (CDS) and core 
outcome sets (COS) in specific health conditions has been routinely recommended.174–176 Core 
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outcomes are instruments (e.g., EURoQOL scale, PROMIS Emotional Distress - Depression 
scale) that measure particular core domains (e.g., quality of life, depression, pain), the latter of 
which are specific symptoms or broader symptom categories. A CDS is an agreed upon 
selection of symptoms or symptom domains (categories) that should be measured and reported 
in all clinical trials for a particular health condition. A COS is defined as an agreed minimum 
selection of outcomes that should be measured and reported in all clinical trials for a particular 
health condition.176 CDSs must be developed prior to the development of COSs of measurement 
instruments. Given that the scientific community has only recently started to examine Long 
COVID, a CDS is the first necessary step. A CDS would increase the reporting of patient 
important outcomes in Long COVID, reduce the risk of selective outcome reporting,177 and 
increase the feasibility of conducting meta-analyses on such topics in the future.174,177 In relation to 
value-based health care, core domain and outcome sets are key to performing research that 
inform quality indicators related directly to patient outcomes and are routinely being used by 
national health-care organizations in the USA and abroad178–184 and in particular can be used in 
the measurement of quality of care in the COVID era.185 
 
Some work has been done to create various types of CDSs and COSs for clinical trials 
of acute COVID-19.170,186–188 While this work is important for the acute period of COVID-19, these 
efforts do not focus on the long-term outcomes associated with Long COVID. To date no work 
has been done to explore what is important to patients with Long COVID. Without a CDS 
informed by a large sample of patients that had COVID-19, clinicians and clinical trialists will 
lack an essential assessment tool to adequately measure patient specific and patient important 
outcomes and changes across time. A CDS would provide a critical means of comparing results 
across trials, which is extremely difficult in the current conditions where many different PROMs 
are being used in many different samples of patients. 
 
These problems undermine the relevance and usefulness of this evidence for decision-
making, and the research does not focus on what is most important to patients. Because 
evidence suggests long-term effects of COVID-19 on health-related quality of life, working to 
identify the domains and corresponding measures (e.g., Patient Reported Outcomes 
Measurement Information System [PROMIS] item banks) that are most relevant to COVID-19 
patients following the acute infection is urgently needed given the rapid expansion of clinical 
research in this group. The incidence of those with Long COVID will climb, and soon much 
clinical care and research will be directed at this group, as evidenced by the increase in 
research in the area. 
Importance of Defining Long COVID 
Available evidence suggests that Long COVID is a substantial public health problem with 
severe consequences for affected individuals and society at large. Patients commonly report 
being emotionally affected by health problems related to Long COVID. In the United States, 
patients have reported mild to severe financial impacts related to acute or chronic COVID-19,77,189 
This concern is underscored by reports that Long COVID patients experience increased 
disability related to breathlessness and decreased quality of life.190 Understanding the needs of 
these patients will allow for the development of healthcare, rehabilitation, and other resources 
needed to support their recovery.191,192 However, identifying patient needs is contingent on 
developing a research infrastructure that accurately assesses the natural history of this illness. 
 
Given the heterogeneity of clinical presentations of individuals with prolonged clinical 
manifestations following acute COVID-19, it is likely that clinical management should be tailored 
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to individuals. However, the clinical management of Long COVID remains challenging because 
there are no evidence-based guidelines. Existing studies do not always provide comprehensive 
information about the clinical course, and often present aggregated results for individuals with 
differing clinical courses, such as for instance severe COVID requiring admission to an ICU and 
moderate COVID requiring hospitalization but not care in the ICU. Existing literature is 
contradictory with respect to the natural history of Long COVID. For instance, one study found 
that persistent fatigue is independent of severity of initial infection, but another found that 10 of 
16 individuals (63%) with severe acute COVID-19 but only 26/65 (40%) individuals with 
moderate COVID had persistent fatigue.73 It should be noted that available studies have 
investigated COVID-19 patients who have come to medical attention, and much less data are 
available at the population level about the extent of late sequelae.42  
 
Most studies to date use survey-based methods to ascertain patient-reported symptoms 
of Long COVID, although some studies are beginning to use imaging and other technologies to 
identify the physical signs of organ damage. Vital signs are a third category of indicators that are 
likely to prove valuable in efforts to investigate Long COVID. Vital signs have several attractive 
properties for the study of COVID-19. Data are often available from prior to the illness allowing 
for pre-post comparisons and are routinely collected in affected and unaffected individuals 
allowing for case-control comparisons. Moreover, analyses of discontinuities in a vital sign’s 
trajectory of time are possible. An ecosystem where associations between patient-reported 
symptoms, data available in EHR, and results of simple and/or complex clinical assessments 
with Long COVID have been evaluated and standardized will introduce a positive feedback 
cycle where clinicians are able to collect the data needed for the elucidation of Long COVID 
phenotype.  
 
While heterogeneity in the presentation of Long COVID has been identified, the specific 
variables influencing outcomes remain to be characterized. The number of syndromes within 
Long COVID and the extent to which symptom profiles, frequency of occurrence, and duration 
are unique to these groups remains to be explored. At present, however, data is not collected in 
a way to allow for these subtle differences to be parsed. In order to develop clinical 
management strategies to prevent or mitigate Long COVID, it will be essential for studies to use 
a unified definition of Long COVID and its subforms so that data from different studies can be 
integrated to provide the foundation for robust statistical inferences about risk factors for the 
development of Long COVID, as well as the natural history and response to treatments.  
 
Among the reasons for needing an unambiguous definition of Long COVID is the need to 
make clear contrasts and comparisons between affected and unaffected people. In addition, a 
clear definition is necessary to understand whether or to what extent defining phenotypic 
features of Long COVID were present prior to COVID-19 illness in patients affected by Long 
COVID or potentially serving as controls in studies. The identification of appropriate unaffected 
people and pre-illness time periods for comparisons is foundational to advancing the state of the 
art in Long COVID research. It is imperative that patient-reported symptoms be taken into 
account alongside deep clinical characterization and large scale observational data such as in 
the N3C. However, all three sources of data are subject to biases and all sources are needed to 
provide a more complete picture of Long COVID characterization for individuals and 
populations. 
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The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance 
Protocol # IRB00249128 or individual site agreements with NIH. 
Use of the N3C data for this study is authorized under the following IRB Protocol: 




University of North 
Carolina University of North Carolina Chapel Hill Institutional Review Board exempted 21-0309 
Stony Brook 
University 
Office of Research Compliance, Division of Human Subject 




The N3C Data Enclave is approved under the authority of the NIH Institutional Review Board for 
Protocol 000082 associated with NIH iRIS reference number: 546652 entitled: “NCATS National 
COVID-19 Cohort Collaborative (N3C) Data Enclave Repository.” Further information can be 
found at ncats.nih.gov/n3c/resources. 
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